# SWOG GAP (NCT04871529)

> Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

No report yet. It can be ordered.

- Drugs tested: avelumab plus gemcitabine plus carboplatin
- Indication: cisplatin-ineligible muscle-invasive urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04871529
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: SWOG Cancer Research Network
- Conditions: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8
- Interventions: Therapeutic Conventional Surgery; Avelumab; Gemcitabine Hydrochloride; Carboplatin
- Enrollment: 6
- Primary outcome: Pathologic Complete Response

## Indexed commentary on SWOG GAP so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=swog-gap-nct04871529